Claritas Pharmaceuticals, Inc.
Claritas Pharmaceuticals, Inc. (CLAZF) Shares Outstanding — Overview
Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.
CLAZF · shares outstanding · updated Jun 9, 2026
Key metrics
as of Dec 31, 2020Shares Outstanding Growth Rate
CAGR · weighted avg basic sharesNegative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials
Shares outstanding history
Annual shares outstanding by year
Healthcare sector shares outstanding comparison
Shares Outstanding for similar companies or competitors in the Healthcare sector.
MRK
JNJ
ABBV
AZN
UNH
LLYCLAZF/company-screener · per-peer /income-statement · cache 86400s
Understanding Shares Outstanding
Basic · Diluted · FloatWhat Are Shares Outstanding? (Basic)
Claritas Pharmaceuticals, Inc. (CLAZF) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2020, Claritas Pharmaceuticals, Inc. reports 26.7M basic shares outstanding (weighted average).
Basic vs. Diluted Shares Outstanding
Claritas Pharmaceuticals, Inc.'s basic shares outstanding (26.7M) represents currently issued shares. Diluted shares outstanding (26.7M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.
Shares Outstanding vs. Float (Free Float)
Claritas Pharmaceuticals, Inc.'s float is 30.4M (83.2% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.
ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.
FMP /income-statement · /shares-float · SEC EDGAR · USD
About shares outstanding & methodology
Claritas Pharmaceuticals, Inc. (CLAZF) shares outstanding history from 2005 to 2020. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.
Claritas Pharmaceuticals, Inc. shares outstanding for the fiscal year ending December 31, 2020 were 26.7M, a 18.94% increase year-over-year. Claritas Pharmaceuticals, Inc. FY 2020 shares outstanding were 26.7M, a +18.94% increase from FY 2019.
Claritas Pharmaceuticals, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +88.7% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.
Frequently asked questions
CLAZF shares outstanding · 4 questionsAs of December 31, 2020, Claritas Pharmaceuticals, Inc. (CLAZF) has approximately 26.7M basic shares outstanding and 26.7M diluted shares outstanding. This represents a +18.94% year-over-year increase from FY 2019 (22.4M). The increase may reflect equity compensation issuances or secondary offerings.
▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Claritas Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09